Effects of regulation ROS on the pain and the protein of Pink1 in spinal of SNI mice and its mechannism

doi:10.12092/j.issn.1009-2501.2019.11.008

Abstract

Abstract:

AIM: To observe the effect of oxidative stress on the expression of Pink1 in mechanical pain and spinal cord after C57/BL6 mice with spared nerve injury (SNI), and to explore the possible effects and mechanism of oxidative stress on Pink1 in neuropathic pain. METHODS: Sixty mice were randomly divided into Control group, Sham group (Sham), Surgery group (SNI), SNI+Saline, and SNI+phenyl-N-tert-butylnitrone (PBN). The Control group received no treatment. The Sham group was cut the skin and separated the three branches of the sciatic nerve to suture the skin. The SNI group was freed and retained the branches of the sacral nerve, and ligated and cut the phrenic nerve. The mechanical pain threshold was detected after 14 days. After the behavioral test, the SNI group was injected with 0.9% physiological saline and PBN. Behavioral measurements were performed and oxidative stress (GSH, SOD) levels were measured. Western blot was used to detect the expression of Pink1 in the lumbar spinal cord protein in each group. RESULTS:Compared with the Control and Sham groups, the mechanical pain threshold was significantly lower in the SNI group (P<0.001); In the SNI group, the ROS level in the lumbar spinal cord was increased (P<0.05), and the ROS level was decreased after PBN injection (P<0.001); Pink1 expression was increased at the protein level in SNI mice (P<0.001), and the expression of Pink1 in the spinal cord decreased after ROS decreased (P<0.01). CONCLUSION:Pink1 is highly expressed in the protein level in the spared nerve injury, and reduced ROS level can improve the expression of Pink1 in neuropathic pain of mice.

Key words: spared nerve injury, mitochondria, Pink1, ROS, mice

CLC Number:

R965.2
R741

CAI Miaoguo, SHAO Wei, YU Huijun, HONG Ye, SHI Lili. Effects of regulation ROS on the pain and the protein of Pink1 in spinal of SNI mice and its mechannism[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1263-1268.

References

［1］Sanna MD, Lucarini L, Durante M, et al. Histamine H4 receptor agonist-induced relief from painful peripheral neuropathy is mediated by inhibition of spinal neuroinflammation and oxidative stress［J］. Br J Pharmacol, 2017, 174(1): 28-40.
［2］Bennett DL. Informed drug choices for neuropathic pain［J］. Lancet Neurol, 2015, 14(2): 129-130.
［3］Busse JW, Wang L, Kamaleldin M, et al. Opioids for chronic noncancer pain: A systematic review and meta-analysis ［J］. JAMA, 2018, 320(23): 2448-2460.
［4］Li ZH,Cui D,Qiu CJ,et al.Cyclic nucleotide signaling in sensory neuron hyperexcitability and chronic pain after nerve injury［J］.Neurobiol Pain,2019,6:100028.
［5］Yamada EF, Salgueiro AF, Goulart A, et al. Evaluation of monosodium iodoacetate dosage to induce knee osteoarthritis: Relation with oxidative stress and pain ［J］. Int J Rheum Dis, 2019, 22(3): 399-410.
［6］Magar S, Nayak D, Mahajan UB, et al. Retraction note: Ultra-diluted toxicodendron pubescens attenuates pro-inflammatory cytokines and ROS- mediated neuropathic pain in rats ［J］. Sci Rep, 2019, 9(1): 8641.
［7］Wang H, Song T, Wang W, et al. TRPM2 participates the transformation of acute pain to chronic pain during injury-induced neuropathic pain ［J］. Synapse, 2019: e22117.
［8］Churyukanov MV,Shevtsova GE,Zagorulko OI.A neuropathic component of lumboischialgia:mechanisms of development and treatment approaches［J］.Zh Nevrol Psikhiatr Im S S Korsakova,2017,117(1):90-96.
［9］马冰洁，刘晓明，马柯. 转运蛋白在背根神经节参与调控神经病理性疼痛的机制研究［J］. 中国疼痛医学杂志，2017, 23(6): 414-420.
［10］Lu C, Sun X, Wang C, et al. Mechanisms and treatment of painful neuromas ［J］. Rev Neurosci, 2018, 29(5): 557-566.
［11］Hong L, Jagadeeswaran R, Molokie R, et al. Selenium deficiency in a mouse model of sickle cell disease resulted in increased oxygen consumption and aberrant mitochondrial retention (OR11-05-19) ［J］. Curr Dev Nutr, 2019, 3(Suppl 1).
［12］Trecarichi A,Flatters S.Mitochondrial dysfunction in the pathogenesis of chemotherapy-induced peripheral neuropathy［J］.Int Rev Neurobiol,2019,145:83-126.
［13］Calvo M, Dawes JM, Bennett DL. The role of the immune system in the generation of neuropathic pain ［J］. Lancet Neurol, 2012, 11(7): 629-642.
［14］Nie F, Wang J, Su D, et al. Abnormal activation of complement C3 in the spinal dorsal horn is closely associated with progression of neuropathic pain ［J］. Int J Mol Med,2013, 31(6): 1333-1342.
［15］Federico A, Cardaioli E, Da PP, et al. Mitochondria, oxidative stress and neurodegeneration ［J］. J Neurol Sci, 2012, 322(1/2): 254-262.
［16］Xu B, Zhu L, Chu J, et al. Esculetin improves cognitive impairments induced by transient cerebral ischaemia and reperfusion in mice via regulation of mitochondrial fragmentation and mitophagy ［J］. Behav Brain Res, 2019, 372: 112007.
［17］Rodriguez-Rocha H,Garcia-Garcia A,Pickett C,et al.Compartmentalized oxidative stress in dopaminergic cell death induced by pesticides and complex I inhibitors:distinct roles of superoxide anion and superoxide dismutases［J］.Free Radic Biol Med,2013,61:370-383.
［18］Candas D,Li JJ.MnSOD in oxidative stress response-potential regulation via mitochondrial protein influx［J］.Antioxid Redox Signal,2014,20(10):1599-1617.
［19］Naziroglu M,Dikici DM,Dursun S.Role of oxidative stress and Ca(2)(+) signaling on molecular pathways of neuropathic pain in diabetes:focus on TRP channels［J］.Neurochem Res,2012,37(10):2065-2075.
［20］Xiang RL, Huang Y, Zhang Y, et al. Type 2 diabetes-induced hyposalivation of the submandibular gland through PINK1/Parkin-mediated mitophagy ［J］. J Cell Physiol, 2019:1-13.
［21］Joselin AP, Hewitt SJ, Callaghan SM, et al. ROS-dependent regulation of Parkin and DJ-1 localization during oxidative stress in neurons ［J］. Hum Mol Genet, 2012, 21(22): 4888-4903.
［22］Schloss JM, Colosimo M, Airey C, et al. Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review ［J］. Clin Nutr, 2013, 32(6): 888-893.

[1]	LIU Lijing, QIAN Hong, MENG Qingxin, ZHANG Xiang, HE Bin, HE Jianbin, WEI Yingmin. Sinomenine inhibits oxidative stress and pulmonary fibrosis by activating the Keap1/Nrf2 signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 979-987.
[2]	WANG Jingang, LI Qiang, SUN Huiyan, WANG Hongquan. Recent progress in understanding the neuroprotective mechanism of carnosic acid in Parkinson's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1073-1080.
[3]	FU Xiaoyu, KONG Deguang, LI Juanjuan. Treatment progress of triple positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
[4]	LI Shixu, LI Linyun, WANG Xin, LI Ke, BIAN Hua. Effects of Ginkgo biloba extract on renal injury in rats with experimental renal failure through miR-145/FOXO1 axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 728-735.
[5]	LI Yating, YUE Hongmei, LIU Miaomiao, XU Jinhui, WU Xingdong, ZHU Haobin. The possibility of phosphodiesterase 4 inhibitors as drug therapy for idiopathic pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 818-823.
[6]	ZHAO Lingzhi, HE Yanjun, XIE Jianqin, YOU Chongge. Research progress on therapeutic role of recombinant human soluble thrombomodulin in atherosclerosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 832-840.
[7]	XIE Jingjing, YIN Hongtao, LIU Jinjin, SUN Weiming, ZHEN Donghu. Baseline serum 25-hydroxyvitamin D3 levels and risk of metabolic syndrome: a prospective cohort study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 641-652.
[8]	HU Kangyi, CAO Linzhong, WAN Chaochao, SHANG Zhengya, YANG Xiaorui, ZHANG Yongjie. Research progress of traditional Chinese medicine regulating mitochondrial function in the treatment of steroid-induced femoral head necrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 688-696.
[9]	XU Wei, CHEN Feng, YE Zhijun. Effectss of hyperoside on traumatic brain injury rats by regulating RhoA/ROCK signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 383-390.
[10]	ZHANG Xuejiao, LIU Jieting, LI Luxin, CHEN Peijian, DING Minglu, SUN Mengwei, CHU Yanhui, ZHANG Zhen . Effects and mechanism of dapagliflozin on myocardial injury in type 1 diabetes mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 257-265.
[11]	CAO Fang, QIN Kairong, ZHENG Guoshuang, ZHAO Dewei. Exploring the intervention mechanism of Ginkgo biloba for steroid-induced necrosis of the femoral head based on network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 266-275.
[12]	LI Junmin, NIU Hengli, XIE Mingquan, SU Jinlong. Effects of hawthorn flavonoids on atherosclerotic and hyperlipidemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 276-282.
[13]	SHEN Jiaqing, LIU Yi. Mechanism of tyrosine kinase 2 inhibitors in treatment of plaque psoriasis and their progress in clinical trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 323-330.
[14]	ZHANG Li, LIN Xingyao, SHANG Yun, WANG Qiang. Progress on the pathological mechanism and treatment of frostbite [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 347-354.
[15]	LIU Nanyu, YUE Hongmei, SONG Peipei, WEI Jifang, WEI Yaqian, XIE Yingying, WANG Jiaqi . PDE4 inhibitors serve as therapeutic targets for pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 355-360.